DCCR

Portnoy Law Firm launches class action lawsuit against $SLNO alleging concealment of safety issues in lead drug DCCR, following 27% stock plunge.

Securities class action filed against $SLNO over alleged misstatements about Prader-Willi drug safety risks. Lead plaintiff deadline set for May 5, 2026.

Soleno Therapeutics faces securities litigation alleging undisclosed DCCR safety risks during March-November 2025. Lead plaintiff deadline: May 5, 2026.

Securities class action filed against $SLNO over alleged false statements regarding safety risks in Phase 3 trial for Prader-Willi syndrome treatment. Lead plaintiff deadline: May 5, 2026.

Portnoy Law Firm sues Soleno Therapeutics for allegedly concealing DCCR safety risks in Phase 3 trials, citing 27% stock drop on November 4, 2025.

Securities lawsuit alleges $SLNO concealed safety concerns about DCCR, its only commercial product for Prader-Willi syndrome treatment, ahead of May 5, 2026 lead plaintiff deadline.

Soleno Therapeutics faces securities lawsuit alleging undisclosed safety risks in its sole commercial product DCCR. Investors have until May 5, 2026 to seek lead plaintiff status.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.

Law firm Kahn Swick & Foti alleges Soleno Therapeutics failed to disclose material safety concerns with its flagship DCCR product, with lead plaintiff applications due May 5, 2026.

Rosen Law Firm files securities class action against $SLNO for alleged misstatements regarding safety concerns with DCCR drug candidate for Prader-Willi syndrome treatment.

Class action lawsuit filed against Soleno Therapeutics for allegedly failing to disclose material safety concerns about its DCCR product. Investors can apply as lead plaintiff by May 5, 2026.